title: Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?
abstract: Many patients suffering from major psychiatric disorders do not respond adequately to monotherapy and require additional drugs. To date, there are no objective guidelines for deciding which combination may be effective, and the choice is based on previous clinical experience and on trial and error. Even when combination drugs are effective, the biochemical mechanisms responsible for the value-added effect are unknown. Understanding the mechanism of such synergism may provide a rational basis for choosing drug combinations and for developing more effective drugs. In schizophrenia, negative symptoms respond poorly to antipsychotics, but may improve when these are augmented with selective serotonin reuptake inhibitors (SSRI). This augmenting effect cannot be explained by summating the pharmacological effects of the individual drugs. We proposed that the study of SSRI augmentation can serve as a window to understanding the biochemical mechanisms of clinically effective drug synergism. In a series of studies we identified unique biochemical effects of the combination, different from each individual drug, and proposed that some of these are involved in mediating the clinical effect. Here we review some of the findings and propose that the mechanism of action involves regionally selective modulation of the GABA system. The evidence indicates that the SSRI antidepressant-antipsychotic combination may be a useful paradigm for studying therapeutically effective synergistic drug interactions in schizophrenia. Although as yet limited in scope, the findings of definable molecular targets for synergistic SSRI-antipsychotic interaction provide new directions to inform future research and provide novel bio-molecular targets for drug development.
authors.affiliation: Molecular Neuropsychiatry Unit, Brain Behavior Laboratory, Shaar Menashe Mental Health Center, and Technion-Faculty of Medicine, Haifa 32000, Israel. mdsilver@tx.technion.ac.il
authors.forename: Henry
authors.initials: H
authors.lastname: Silver
authors.forename: Yael
authors.initials: Y
authors.lastname: Chertkow
authors.forename: Orly
authors.initials: O
authors.lastname: Weinreb
authors.forename: Lena
authors.initials: L
authors.lastname: Danovich
authors.forename: Moussa
authors.initials: M
authors.lastname: Youdim
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015306:Biogenic Monoamines / Q000378:metabolism; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015398:Signal Transduction; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D015306:Biogenic Monoamines; D017367:Selective Serotonin Reuptake Inhibitors; D005680:gamma-Aminobutyric Acid